A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.
While findings from the high-profile AMP studies have excited scientists, they’re only one of a wide range of bNAb avenues currently being pursued.
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.
David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.
David Alain Wohl, M.D., talks through new data regarding long-acting antiretroviral therapy for HIV—and touches on the uncertainties clinicians face in incorporating this new treatment method into their practice.
CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.
Jan. 7, 2021: HIV status and COVID-19 disease severity; associations between tobacco smoking, cancer incidence, viral load, and CD4 count; immune recovery on integrase inhibitors; using smart pill bottles to boost adherence.
“You could think of this as ‘who is in and who is out,’ but in reality [restructuring] is more like changing chairs,” said Carl Dieffenbach, Ph.D.
U.S. Waits on Approval of Long-Acting HIV Treatment Cabotegravir and Rilpivirine as European Union Gives the Green Light
The era of once-a-month HIV treatment has begun in the European Union—and it may soon commence in the U.S. as well. Long-acting pre-exposure prophylaxis (PrEP) is also on the horizon.
This year, we got exciting new data about an HIV drug in development that may become an every-six-month, self-administered antiretroviral injection. But we learned about it via press release, rather than carefully presented research.